Trismus (dichotomous, 7th day) · People undergoing tooth extraction (21 of 23 trials: healthy patients undergoing impacted third molar extraction; 1 routine intra-alveolar…
It is very uncertain whether systemic antibiotic prophylaxis (any regimen; topical therapy… changes trismus (dichotomous, 7th day) compared with placebo (very low certainty).
1 finding from 1 review
Systemic antibiotic prophylaxis (any regimen; topical therapy excluded) administered before and/or after tooth extraction vs Placebo
Outcome not reported · Immunosuppressed / immunocompromised patients (e.g. HIV infection, AIDS, diabetes, transplants) undergoing tooth extraction
The review found no eligible studies for this question.
1 finding from 1 review
Fever · People undergoing tooth extraction (21 of 23 trials: healthy patients undergoing impacted third molar extraction; 1 routine intra-alveolar…
It is very uncertain whether systemic antibiotic prophylaxis (any regimen; topical therapy… changes fever (6th-7th day) compared with placebo (very low certainty).
1 finding from 1 review
Systemic antibiotic prophylaxis (any regimen; topical therapy excluded) administered before and/or after tooth extraction vs Placebo
Outcome not reported · Patients undergoing tooth extraction for severe dental caries or periodontal disease in general dental practice (non-third-molar / decayed…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events (any) · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether synbiotic changes adverse events (any) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (any) · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether probiotic changes adverse events (any) compared with placebo (very low certainty).
1 finding from 1 review
Change in any GI upset (borborygmi) · people with CKD
It is very uncertain whether synbiotic changes change in any GI upset (borborygmi) compared with prebiotic (very low certainty).
1 finding from 1 review
Change in any GI upset (GSRS total index) · people with CKD
1 finding from 1 review
Change in any GI upset or intolerance · people with CKD
1 finding from 1 review
Change in any GI upset or intolerance · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in any GI upset or intolerance · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in any GI upset or intolerance · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in any GI upset or intolerance · people with CKD
1 finding from 1 review
Change in any GI upset or intolerance · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in any GI upset or intolerance (abdominal pain/diarrhoea) · people with CKD
It is very uncertain whether probiotic changes change in any GI upset or intolerance (abdominal pain/diarrhoea) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Change in any GI upset or intolerance (constipation) · people with CKD
It is very uncertain whether probiotic changes change in any GI upset or intolerance (constipation) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).
1 finding from 1 review
Number experiencing adverse effects · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: amikacin liposome inhalation suspension (ALIS) showed no clear difference in adverse events: number of participants experiencing any TEAE compared with tobramycin (moderate certainty).
1 finding from 1 review
Adverse events: any adverse event in the comparative phase · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: continuous cycles alternating aztreonam lysine… showed no clear difference in adverse events: any adverse event in the comparative phase compared with continuous cycles alternating placebo with tobramycin (low certainty).
1 finding from 1 review
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review